E. G. Lowrie, J. M. Lazarus, and A. J. Mocelin, Survival of Patients Undergoing Chronic Hemodialysis and Renal Transplantation, N. Engl. J. Med, vol.288, issue.17, pp.863-867, 1973.

M. Wyld, R. L. Morton, A. Hayen, K. Howard, and A. C. Webster, A Systematic Review and MetaAnalysis of Utility-Based Quality of Life in Chronic Kidney Disease Treatments, PLoS Med, vol.9, issue.9, p.1001307, 2012.

G. A. De-wit, P. G. Ramsteijn, and F. T. De-charro, Economic evaluation of end stage renal disease treatment, Health Policy, vol.44, issue.3, pp.215-232, 1998.

J. M. Morales, R. Marcen, and D. Del-castillo, Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study, Nephrol. Dial. Transplant, vol.27, issue.4, pp.39-46, 2012.

J. Sellarés, D. G. De-freitas, and M. Mengel, Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence, Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg, vol.12, issue.2, pp.388-399, 2012.

C. Wiebe, I. W. Gibson, and T. D. Blydt-hansen, Rates and Determinants of Progression to Graft Failure in Kidney Allograft Recipients With De Novo Donor-Specific Antibody, Am. J. Transplant, vol.15, issue.11, pp.2921-2930, 2015.

M. J. Everly, L. M. Rebellato, and C. E. Haisch, Incidence and impact of de novo donor-specific alloantibody in primary renal allografts, Transplantation, vol.95, issue.3, pp.410-417, 2013.

A. Sicard, S. Ducreux, and M. Rabeyrin, Detection of C3d-Binding Donor-Specific Anti-HLA Antibodies at Diagnosis of Humoral Rejection Predicts Renal Graft Loss, J. Am. Soc. Nephrol, vol.26, issue.2, pp.457-467, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01910934

M. Haas, A. Loupy, and C. Lefaucheur, Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials, Am. J. Transplant, vol.18, issue.2, pp.293-307, 2017.

P. F. Halloran, Immunosuppressive Drugs for Kidney Transplantation, N. Engl. J. Med, vol.351, issue.26, pp.2715-2729, 2004.

T. Bertani, P. Ferrazzi, and A. Schieppati, Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients, Kidney Int, vol.40, issue.2, pp.243-250, 1991.

E. Pillebout, D. Nochy, and G. Hill, Renal Histopathological Lesions After Orthotopic Liver Transplantation (OLT), Am. J. Transplant, vol.5, issue.5, pp.1120-1129

B. D. Myers and L. Newton, Obliterative Microvascular Renal Injury, J. Am. Soc. Nephrol, vol.8

, Chronic Renal Failure after Transplantation of a Nonrenal Organ, N. Engl. J. Med, vol.10, 2003.

D. Ducloux, G. Motte, and M. Kribs, Hypertension in renal transplantation: donor and recipient risk factors, Clin. Nephrol, vol.57, issue.6, pp.409-413, 2002.

I. Berber, C. Aydin, and B. Yigit, Blood pressure and graft outcome in renal transplantation, Transplant. Proc, vol.37, issue.2, pp.997-998, 2005.

M. Roland, P. Gatault, and C. Doute, Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation, Transpl. Int. Off. J. Eur. Soc. Organ Transplant, vol.21, issue.6, pp.523-530, 2008.

F. Vincenti, S. Friman, and E. Scheuermann, Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus, Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg, vol.7, issue.6, pp.1506-1514, 2007.

A. J. Matas, K. J. Gillingham, and A. Humar, Posttransplant diabetes mellitus and acute rejection: impact on kidney transplant outcome, Transplantation, vol.85, issue.3, pp.338-343, 2008.

A. S. Mathis, N. Davé, G. T. Knipp, and G. S. Friedman, Drug-related dyslipidemia after renal transplantation, Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm, vol.61, issue.6, pp.586-587, 2004.

C. P. Larsen, T. C. Pearson, and A. B. Adams,

, High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties, Am. J. Transplant, vol.5, issue.3, pp.443-453, 2005.

S. Gupta, I. Rosales, and D. Wojciechowski, Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic tacrolimus Toxicity, J. Transplant, vol.2018, pp.1-6, 2018.

M. Paz, J. Roberti, F. Mos, and F. Cicora, Conversion to belatacept-based immunosuppression therapy in renal transplant patients, Transplant. Proc, vol.46, issue.9, pp.2987-2990, 2014.

K. Schulte, C. Vollmer, and V. Klasen, Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism, J. Nephrol, vol.30, issue.4, pp.607-615, 2017.

Q. Lin, Y. Song, X. Zhu, S. Yang, and J. Zheng,

X. Chin, J. Cell. Mol. Immunol, vol.29, issue.2, pp.137-140, 2013.

D. Whiting, G. Hsieh, and J. J. Yun, Chemokine Monokine Induced by IFN-?/CXC Chemokine Ligand 9 Stimulates T Lymphocyte Proliferation and Effector Cytokine Production, J. Immunol, vol.172, issue.12, pp.7417-7424, 2004.

H. Hu, J. Kwun, B. D. Aizenstein, and S. J. Knechtle, Noninvasive Detection of Acute and Chronic Injuries in Human Renal Transplant by Elevation of Multiple Cytokines/Chemokines in Urine, Transplantation, vol.87, issue.12, pp.1814-1820, 2009.

M. Rabant, L. Amrouche, and L. Morin, Early Low Urinary CXCL9 and CXCL10 Might Predict Immunological Quiescence in Clinically and Histologically Stable Kidney Recipients, Am. J. Transplant, vol.16, issue.6, pp.1868-1881, 2016.

D. E. Hricik, P. Nickerson, and R. N. Formica, Multicenter Validation of Urinary CXCL9 as a RiskStratifying Biomarker for Kidney Transplant Injury, Am. J. Transplant, vol.13, issue.10, pp.2634-2644

C. Leibler, M. Matignon, and C. Pilon, Kidney Transplant Recipients Treated With Belatacept Exhibit Increased Naïve and Transitional B Cells: B Cell Phenotype in Belatacept-Treated KT Patients, Am. J. Transplant, vol.14, issue.5, pp.1173-1182, 2014.

M. Matz, K. Fabritius, and J. Liu, Conversion to Belatacept based regimen does not change Tcell phenotype and function in renal transplantation, Transpl. Immunol, vol.33, issue.3, pp.176-184, 2015.

A. Darres, C. Ulloa, and S. Brakemeier, Conversion to belatacept in maintenance kidneytransplant patients: A retrospective multicenter European study, Transplantation, vol.1, 2018.

I. Gandolfini, C. Harris, and M. Abecassis, Rapid Biolayer Interferometry Measurements of

, Urinary CXCL9 to Detect Cellular Infiltrates Noninvasively After Kidney Transplantation. Kidney Int. Rep, vol.2, issue.6, pp.1186-1193, 2017.

L. Rostaing, F. Vincenti, and J. Grinyó, Long-Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long-Term Extension of the BENEFIT Study: BENEFIT Long-Term Extension, Am. J. Transplant, vol.13, issue.11, pp.2875-2883, 2013.

Y. Vanrenterghem, B. Bresnahan, and J. Campistol, Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies): Transplantation, vol.91, pp.976-983, 2011.
DOI : 10.1097/tp.0b013e31820c10eb

Z. Li, F. Sun, and Y. Zhang, tacrolimus Induces Insulin Resistance and Increases the Glucose Absorption in the Jejunum: A Potential Mechanism of the Diabetogenic Effects, PLoS ONE, vol.10, issue.11, 2015.

G. N. De-graav, D. A. Hesselink, and M. Dieterich, Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells, PLOS ONE, vol.11, issue.2, p.148604, 2016.